Custom Synthesis is our business  


China CRO 2010 Charts the Changes in the Chinese CRO Industry: The Year of Mergers and Acquisitions

SHANGHAI--()--The authoritative guide to contract research organizations in China is now available to international drug and medical device developers. The directory, China CRO 2010, summarizes the major changes in the past year and offers the most comprehensive and up-to-date directory of service providers for drug and device development in China.

“The landscape of global CROs in China has completely changed in the past year”

“The landscape of global CROs in China has completely changed in the past year,” said Chloe Liu, Ph.D., managing partner of Modular R&D, which produces the directory. “Through a series of acquisitions and organic new openings, the number of global CROs operating in China has doubled. The acquisition activity comes in part from leading CROs trying to gain dominance in the Chinese market and in part from CROs new to China trying to quickly establish themselves through developed local firms.” Global CROs are also expanding their service offerings and moving into new therapeutic areas in China. There has been an especially big increase in the number of companies offering services in central labs and drug supply management.

Local firms are growing as well. Reputable local CROs are using mergers, acquisitions and partnerships to expand service offerings and gain clients in order to compete with global CROs. New CROs are being formed, some backed by local governments, some funded by VC investment. Some advanced institutional service providers, such as some SFDA-certified GLP labs, are starting to act as commercial entities, opening up services to international drug developers. To attract international clients, many existing companies are improving services by obtaining international accreditation such as AAALAC and CAP.

China CRO 2010 lists 168 verified CROs offering drug discovery, preclinical studies and clinical trials. The industry is made up of global CROs (15%), domestic CROs (54%), and CROs based in China but with international reach (31%). 111 offer services in clinical trials, 35 offer drug discovery services and 36 offer preclinical studies.

The new edition of the directory has 20-30% new information, taking into account the latest acquisitions such as PPD’s of Excel Pharmastudies and Bioduro, RPS of Paramax, INC Research of MDS Clinical Research, i3 Research of Chinagate, Pharmaron of Bridge Pharma, and Tigermed of Macrostat, as well as new service offerings such as Quintiles’ new data management center. China CRO 2010 is a searchable online database, with detailed service categorization, verified contact information and easy access to research and communications.